Scorpius Holdings Discloses Imminent Cash Depletion, Warns of Bankruptcy Risk by End of February 2026
summarizeSummary
Scorpius Holdings, Inc. filed its Q3 2025 report, revealing cash and equivalents of less than $0.1 million as of February 17, 2026, sufficient only through February 2026, and reiterating substantial doubt about its ability to continue as a going concern.
check_boxKey Events
-
Imminent Liquidity Crisis
Cash and cash equivalents stood at less than $0.1 million as of February 17, 2026, with funds projected to last only through the end of February 2026.
-
Going Concern Warning
Management explicitly stated substantial doubt about the company's ability to continue as a going concern, citing no revenue-generating assets and the need for immediate financing or a strategic transaction to avoid bankruptcy or liquidation.
-
Shell Company Status Confirmed
The company reiterated its status as a 'shell company' following the December 10, 2025, foreclosure sale of substantially all its operating assets, an event previously disclosed on January 29, 2026.
-
Continued Financial Distress
The company reported an accumulated deficit of $303.0 million as of September 30, 2025, and a net loss of $15.8 million for the nine months ended September 30, 2025.
auto_awesomeAnalysis
This 10-Q provides a stark update on Scorpius Holdings' financial viability. While the company's shell status and asset foreclosure were previously disclosed in January 2026 filings, the critical new information is the extremely low cash balance as of the filing date (February 17, 2026) and the explicit statement that funds will only last through the end of February 2026. This indicates an immediate and severe liquidity crisis, making bankruptcy or liquidation highly probable in the very near term without an unforeseen capital injection or strategic alternative. Investors face an almost certain loss of investment.
At the time of this filing, SCPX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $24.5K. The 52-week trading range was $0.00 to $0.80. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.